Interleukin-2 gene therapy of surgical minimal residual tumour disease

International Journal of Cancer

Volumn 76, Issue 1, 1998, Pages 115-119

  Vlk, V ^a,b   Rossner P ^a   Indrova M ^a   Bubenik J ^a   Sobota, V ^a  

^a INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; TUMOR VACCINE;

ANIMAL EXPERIMENT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CELL LABELING; CONTROLLED STUDY; DRUG EFFICACY; GENE THERAPY; IMMUNOLOGICAL MEMORY; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MINIMAL RESIDUAL DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SARCOMA CELL; SOLID TUMOR; TREATMENT OUTCOME; TUMOR REGRESSION; VACCINATION; VACCINE PRODUCTION;

ANIMALS; GENE THERAPY; IMMUNOLOGIC MEMORY; INTERLEUKIN-2; LYMPHOCYTE COUNT; LYMPHOCYTE SUBSETS; METHYLCHOLANTHRENE; MICE; MICE, INBRED C57BL; NEOPLASM, RESIDUAL; SARCOMA, EXPERIMENTAL; TRANSFECTION; VACCINATION;

EID: 2642685575     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980330)76:1<115::AID-IJC18>3.0.CO;2-B     Document Type: Article

References (19)

1. BRIVIO, F., LISSONI, A.G., ALDERI, G., BARNI, S., LAVORATO, F. and FUMAGALLI, L., Preoperative interleukin-2 subcutaneous immunotherapy may prolong the survival time in advanced colorectal cancer patients. Oncology, 53, 263-268 (1996).
2. BUBENÍK, J., Utilization of IL-2 and IL-2 gene transfer for regional immunotherapy of cancer. In: G. Forni, R. Foa, A. Santoni and L. Fratti (eds.), Cytokine-induced tumour immunogenicity. From exogenous molecules to gene therapy, pp. 113-130. Academic Press, London (1994).
3. BUBENÍK, J., Genetically modified tumour vaccines carrying inserted genes for immunoregulatory molecules. Folia Biol. (Praha), 42, 295-304 (1996).
4. BUBENÍK, J., INDROVÁ, M., NĚMEČKOVÁ. Š., MALKOVSKÝ, M., VON BROEN, B., PÁLEK, V. and ANDERLÍKOVÁ, J., Solubilized tumor-associated antigens of methylcholanthrene-induced mouse sarcomas. Comparative studies by in vitro sensitization of lymph node cells, macrophage electrophoretic mobility assay and transplantation test. Int. J. Cancer, 21, 348 (1978).
5. BUBENÍK, J., INDROVÁ, M., PERLMANN, P., BERZINS, K., MACH, O., KRAML, J. and TOULCOVÁ, A., Tumour inhibitory effect of TCGF (IL-2)-containing preparations. Cancer Immunol. Immunother., 19, 57-61 (1985).
6. BUBENÍK, J., PERLMANN. P., INDROVÁ, M., ŠÍMOVÁ, J., JANDLOVÁ, T. and NEUWIRT, J., Growth inhibition of an MC-induced mouse sarcoma by TCGF (IL-2)-containing preparations. Cancer Immunol. Immunother., 14, 205-206 (1983).
7. BUBENÍK, J., ŠÍMOVÁ, J., BUBENÍKOVÁ, D., ZEUTHEN, J. and INDROVÁ, M., Interleukin-2 gene therapy of residual EL-4 leukaemia potentiates the effect of cyclophosphamide pretreatment. J. Cancer Res. clin. Oncol., 121, 39-43 (1995).
8. BUBENÍK, J., ŠÍMOVÁ, J. and JANDLOVÁ, T., Immunotherapy of cancer using local administration of lymphoid cells transformed by IL-2 cDNA and constitutively producing IL-2. Immunol. Lett., 23, 287-292 (1989/1990).
9. BUBENÍK, J. and TURANO, A., Enhancing effect on tumour growth of humoral antibodies against specific transplantation antigens in tumours induced by murine sarcoma virus (Harvey). Nature (Lond.), 22, 928-930 (1968).
10. FLEISCHMANN, D. and KIM, B., Interleukin-2 immunotherapy followed by resection of residual renal cell carcinoma. J. Urol., 145, 938-941 (1991).
11. GANSBACHER, B., BANNERJI, R., DANIELS, B., CRONIN, K., BANNERJI, R. and GILBOA, E., Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. exp. Med., 172, 1217-1224 (1990).
12. HORAN, P.K., MELNICOFF, M.J., JENSEN, B.D. and SLEZAK, S.E., Fluorescent cell labeling for in vivo and in vitro cell tracking. Methods Cell Biol., 33, 469-490 (1990).
13. KARASUYAMA, H. and MELCHERS, F., Establishment of mouse cell lines which constitutively secrete large quantities of interleukin-2, 3, 4 or 5, using modified cDNA expression vectors. Europ. J. Immunol., 18, 97-104 (1988).
14. KEARNEY, J.F., RADBRUCH, A., LIESGANG, B. and RAJEWSKI, K., A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines. J. Immunol., 123, 1548-1550 (1979).
15. ROSENBERG. S.A., The immunotherapy and gene therapy of cancer. J. clin. Oncol., 10, 180-199 (1992).
16. RÖSSNER, P., BUBENÍK, J., INDROVÁ, M., SOBOTA, V., VONDRYS, P., ZEUTHEN, J., JANDLOVÁ. T. and TAKÁČ, M., Genetically modified tumour vaccines: insertion of the IL-2 gene downregulates tumorigenicity more efficiently than insertion of the CD80 gene. Int. J. Oncol., 10, 77-82 (1997).
17. ROTH, J.A. and CRISTIANO, R.J., Gene therapy for cancer: what we have done and where we are going? J. nat. Cancer Inst., 89, 21-39 (1997).
18. TSAI, S.-C.J., GANSBACHER, B., TAIT, L., MILLER, F.R. and HEPPNER, G.H., Induction of antitumor immunity by interleukin-2 gene-transduced mouse mammary tumor cells versus transduced mammary stromal fibroblasts. J. nat. Cancer Inst., 85, 546-553 (1993).
19. ZINKERNAGEL, R.M., Immunology taught by viruses. Science, 271, 173-178 (1996).